Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free ENVB Stock Alerts

Enveric Biosciences (ENVB) Competitors

Enveric Biosciences logo
$2.29 -0.15 (-6.15%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$2.26 -0.04 (-1.53%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ENVB vs. ABVC, MRKR, BRNS, LTRN, and VTGN

Should you buy Enveric Biosciences stock or one of its competitors? MarketBeat compares Enveric Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enveric Biosciences include ABVC BioPharma (ABVC), Marker Therapeutics (MRKR), Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), and VistaGen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry.

How does Enveric Biosciences compare to ABVC BioPharma?

Enveric Biosciences (NASDAQ:ENVB) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Enveric Biosciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ABVC BioPharma's return on equity of -65.11% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enveric BiosciencesN/A -255.43% -193.77%
ABVC BioPharma N/A -65.11%-40.13%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ABVC BioPharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

ABVC BioPharma has higher revenue and earnings than Enveric Biosciences. ABVC BioPharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric BiosciencesN/AN/A-$8.77M-$37.11N/A
ABVC BioPharma$510K53.87-$7.91M-$0.40N/A

In the previous week, Enveric Biosciences had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.87 beat Enveric Biosciences' score of 0.36 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Enveric Biosciences Neutral
ABVC BioPharma Very Positive

Summary

ABVC BioPharma beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks.

How does Enveric Biosciences compare to Marker Therapeutics?

Enveric Biosciences (NASDAQ:ENVB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Enveric Biosciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enveric Biosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -80.86% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enveric BiosciencesN/A -255.43% -193.77%
Marker Therapeutics -343.03%-80.86%-67.04%

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 584.93%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Enveric Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Enveric Biosciences has higher earnings, but lower revenue than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric BiosciencesN/AN/A-$8.77M-$37.11N/A
Marker Therapeutics$3.55M6.86-$12.16M-$0.85N/A

In the previous week, Enveric Biosciences and Enveric Biosciences both had 2 articles in the media. Marker Therapeutics' average media sentiment score of 0.94 beat Enveric Biosciences' score of 0.36 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Enveric Biosciences Neutral
Marker Therapeutics Positive

Summary

Marker Therapeutics beats Enveric Biosciences on 11 of the 14 factors compared between the two stocks.

How does Enveric Biosciences compare to Barinthus Biotherapeutics?

Enveric Biosciences (NASDAQ:ENVB) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric BiosciencesN/AN/A-$8.77M-$37.11N/A
Barinthus BiotherapeuticsN/AN/A-$66.43M-$1.29N/A

Barinthus Biotherapeutics' return on equity of -63.83% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enveric BiosciencesN/A -255.43% -193.77%
Barinthus Biotherapeutics N/A -63.83%-48.77%

Enveric Biosciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.43, indicating that its share price is 143% less volatile than the broader market.

In the previous week, Enveric Biosciences and Enveric Biosciences both had 2 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 0.94 beat Enveric Biosciences' score of 0.36 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Enveric Biosciences Neutral
Barinthus Biotherapeutics Positive

Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 462.59%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Enveric Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Barinthus Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by company insiders. Comparatively, 10.7% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Barinthus Biotherapeutics beats Enveric Biosciences on 9 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Lantern Pharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantern PharmaN/AN/A-$17.12M-$1.57N/A
Enveric BiosciencesN/AN/A-$8.77M-$37.11N/A

Lantern Pharma's return on equity of -150.76% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Lantern PharmaN/A -150.76% -108.38%
Enveric Biosciences N/A -255.43%-193.77%

Lantern Pharma has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

In the previous week, Lantern Pharma had 5 more articles in the media than Enveric Biosciences. MarketBeat recorded 7 mentions for Lantern Pharma and 2 mentions for Enveric Biosciences. Lantern Pharma's average media sentiment score of 0.84 beat Enveric Biosciences' score of 0.36 indicating that Lantern Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Lantern Pharma Positive
Enveric Biosciences Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantern Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lantern Pharma beats Enveric Biosciences on 8 of the 10 factors compared between the two stocks.

How does Enveric Biosciences compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Enveric Biosciences has lower revenue, but higher earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VistaGen Therapeutics$490K52.61-$51.42M-$1.89N/A
Enveric BiosciencesN/AN/A-$8.77M-$37.11N/A

VistaGen Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

VistaGen Therapeutics' return on equity of -109.72% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
VistaGen TherapeuticsN/A -109.72% -89.62%
Enveric Biosciences N/A -255.43%-193.77%

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.87 beat Enveric Biosciences' score of 0.36 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
VistaGen Therapeutics Positive
Enveric Biosciences Neutral

VistaGen Therapeutics currently has a consensus target price of $0.95, suggesting a potential upside of 46.02%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe VistaGen Therapeutics is more favorable than Enveric Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VistaGen Therapeutics
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

VistaGen Therapeutics beats Enveric Biosciences on 9 of the 12 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENVB vs. The Competition

Export
MetricEnveric BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.85M$3.42B$6.34B$12.37B
Dividend YieldN/A2.31%2.80%5.35%
P/E Ratio-0.0618.4720.6625.63
Price / SalesN/A294.84542.6376.59
Price / CashN/A125.2943.2656.33
Price / Book0.336.939.936.97
Net Income-$8.77M$24.11M$3.55B$333.62M
7 Day Performance-19.65%5.89%1.70%1.09%
1 Month Performance12.81%-0.91%0.49%3.08%
1 Year Performance-84.85%74.58%39.41%35.68%

Enveric Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENVB
Enveric Biosciences
0.3976 of 5 stars		$2.29
-6.1%		N/A-85.4%$4.85MN/AN/A20
ABVC
ABVC BioPharma
1.2206 of 5 stars		$1.03
-1.9%		N/A-26.0%$26.71M$510KN/A30
MRKR
Marker Therapeutics
3.1032 of 5 stars		$1.51
-3.2%		$10.00
+562.3%		+30.4%$26.01M$3.55MN/A60
BRNS
Barinthus Biotherapeutics
3.0511 of 5 stars		$0.66
+3.1%		$4.00
+510.7%		-20.1%$25.94MN/AN/A107
LTRN
Lantern Pharma
0.7981 of 5 stars		$2.16
-3.1%		N/A-22.9%$25.21MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel